Figure 1 | Scientific Reports

Figure 1

From: Safety and neurochemical profiles of acute and sub-chronic oral treatment with agmatine sulfate

Figure 1

Experimental timelines of short-term (Experiment 1) and sub-chronic (Experiment 2) agmatine treatment. In Experiment 1, wild-type mice were gavaged with 100 μl saline once daily for two days. During the following 7 days, animals were given saline gavage on days 1–5 but intraperitoneal (IP) injection of saline or agmatine at 40 mg/kg once daily on days 6 and 7, whereas others received daily oral gavage of saline or agmatine at 300, 600 and 900 mg/kg. On day 6, all animals were tested in the elevated plus maze (EPM) and open field (OF) 30 minutes post-treatment. On day 7, animals were sacrificed 30 minutes post-treatment followed by blood (plasma) and brain tissue (hippocampus) collection for quantification of L-arginine and its metabolites. In Experiment 2, wild-type and APP/PS1 transgenic mice received oral gavage of saline or agmatine sulfate at 300 mg/kg once daily for 5 days per week for 8 weeks, then once daily for 7 days a week for a further 7 weeks. On day 71, animals were tested in the EPM and OF 24 h after treatment. On day 105, animals were sacrificed 24 hours after the final treatment of day 104 followed by blood and brain tissue collection for agmatine and putrescine quantification.

Back to article page